NCT03799731 - Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 11, 2018

Primary Completion Date

January 19, 2021

Study Completion Date

February 10, 2021

Conditions

Colorectal Cancer

Interventions

DRUG

GM102

GM102 7 mg/kg weekly

DRUG

Trifluridine/Tipiracil

Lonsurf 35 mg/m² twice daily during 10 days per cycle

DRUG

GM102 expansion

GM102 7 mg/kg weekly after a loading dose of 10 mg/kg q1w during 28-day cycle 1

Trial Locations (5)

Cliniques Universitaires Saint-Luc, Brussels

UZ Gasthuisberg, Ghent

UZ Leuven, Leuven

University Hopistal Olomouc, Olomouc

University Hospital Motol, Prague